MarketCapTrends
CLDX
Celldex Therapeutics Inc. (CLDX)
NASDAQ · Healthcare

Celldex Therapeutics Inc. Shareholder Equity 2009–2025

Celldex Therapeutics Inc. annual/quarterly shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Celldex Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 527.2M, a 29.43% decrease year-over-year.
  • Celldex Therapeutics Inc. shareholder equity for 2025 were 527.2M, a 29.43% decrease from 2024.
  • Celldex Therapeutics Inc. shareholder equity for 2024 were 747.0M, a 74.06% increase from 2023.
  • Celldex Therapeutics Inc. shareholder equity for 2023 were 429.2M, a 31.57% increase from 2022.
  • Celldex Therapeutics Inc. shareholder equity for 2022 were 326.2M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Celldex Therapeutics Inc. Annual Shareholder Equity (Millions of US $)
2025$527
2024$747
2023$429
2022$326
2021$419
2020$209
2019$94
2018$124
2017$236
2016$265
2015$290
2014$212
2013$320
2012$96
2011$69
Celldex Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$527
2024-12-31$747
2023-12-31$429
2022-12-31$326
2021-12-31$419
2020-12-31$209
2019-12-31$94
2018-12-31$124
2017-12-31$236
2016-12-31$265
2015-12-31$290
2014-12-31$212
2013-12-31$320
2012-12-31$96
2011-12-31$69
2010-12-31$75

Celldex Therapeutics Inc. Shareholder Equity — FAQ

Celldex Therapeutics Inc. (CLDX) shareholder equity over the last 17 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see CLDX's shareholder equity history?

The chart and table above show Celldex Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.